Veristat Acquires Biometrics-focused Instat Clinical Research
Veristat, a scientific full-service clinical research organization (CRO) and consultancy, has acquired Instat Clinical Research, an expert biometrics CRO with a 20-year track record of transforming complex data into precise study results.
The acquisition strengthens Veristat’s expertise and solutions in biometrics, one of the most impactful activities in the clinical research workflow. Instat brings complementary proficiencies to Veristat’s global data management, biostatistics, and statistical programming teams, with staff located in the United States and India. Instat has extensive experience partnering with clients to optimize how clinical studies are designed and how data is collected, integrated, and analyzed to meet the requirements of global regulatory organizations across the United States, Europe, and Asia. The addition of the India location complements Veristat’s existing facility in Taipei, offering clients access to a round-the-clock team to contribute timely data and accelerate drug development cycle times.
“Our clients must be able to understand and quickly act on the insights gleaned from their study data in both the trial design and trial execution stages of their programs,” said Patrick Flanagan, Chief Executive Officer of Veristat. “Instat brings a proven track record having supported over 100 sponsor-led clinical studies, authoring over 150 statistical analysis plans, and participating in over 30 regulatory submissions. The addition of Instat’s seasoned talent will further strengthen our ability to help clients bring their drugs and biologics to market faster.”
Both Veristat’s and Instat’s biometrics teams have significant expertise in statistical consulting, clinical data programming, statistical analysis, data management, and project management, supporting the development of complex biologic and drug therapies to treat rare cancers, central nervous system/neurological disorders, endocrine/metabolic disorders, and infectious diseases as well as various other therapeutic areas.
“As biotherapeutics continue to evolve, so does biometrics, the unequivocal underpinning of clinical research,” stated Kyle McBride, CEO and Co-founder of Instat. “Instat possesses the ideal mix of talent, technical acumen, and technology solutions to keep pace with this change and bring statistical understanding across the clinical development lifecycle. On behalf of the entire Instat team, we are thrilled to begin our next chapter with Veristat. Our joining allows us to offer world-class end-to-end services to our clients while acting with the speed and effectiveness our customers have come to rely on.”
More information on Veristat’s biometrics services can be found at https://www.veristat.com/services/biometrics
Veristat is a scientific full-service clinical research organization (CRO) and consultancy that integrates strategic planning, regulatory expertise, and clinical trial execution to rapidly advance the most complex or novel therapies. We collaborate with our clients to support the rapid delivery of their life-changing therapies, helping them make sound decisions amidst uncertainties. Our scientific experts design and conduct the global activities required for any clinical, regulatory, or commercialization program comprehensively and efficiently.
With our focus on novel drug development and nearly 30 years of experience, our versatile approach and bold scientific thinking make the impossible possible. Clients depend on our game-changing expertise and reliable execution for fast results and positive impact to support their biologics and drugs to treat rare cancers, CNS/neurological disorders, endocrine/metabolic disorders, and infectious diseases. We are…Bold. Scientific. Versatile. Veristat.
Since its inception in 2003, Instat has served as a trusted partner to clients in the pharmaceutical, biotechnology, and medical device industries, seamlessly integrating its reliable team of experts to produce quality deliverables and innovative solutions. Instat provides comprehensive biometric (data management and statistical) services for all phases of clinical drug development.
With an average of 27 years of industry experience among senior leadership, Instat experts possess the hands-on expertise to design studies and inform regulatory documents to support clients’ global drug submissions and approvals. It is Instat’s goal that new products will make it to market and into the hands of those striving for healthier lives. This goal begins with a client’s drug development, and when partnered with Instat’s analytical expertise, progress is made together to support a healthier future.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
Lauren L. Brennan, Vice President of Marketing, Veristat
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Mary Kay Expands to Hungary, Elevating Beauty and Empowerment in Central Europe30.11.2023 19:03:00 CET | Press release
Mary Kay Inc., the iconic beauty brand and global advocate for women’s empowerment, is thrilled to announce its expansion into Hungary, a strategic move that marks the company's latest foray into the European market. This expansion coincides with Mary Kay's milestone 60th anniversary, underscoring its enduring legacy of offering unparalleled entrepreneurship opportunities and high-quality skincare and color cosmetics. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231130602889/en/ With Hungary’s rich cultural tapestry, vibrant heritage, and dynamic economy, Mary Kay Inc. is set to introduce a range of initiatives aimed at bolstering the economic empowerment of Hungarian women. (Credit: Mary Kay Inc.) Mary Kay Hungary's operations will be overseen from the Mary Kay Czech Republic's offices in Prague. To celebrate this momentous expansion, events in both Prague and Budapest have been arranged. This expansion builds upon the br
Q4 Inc. Announces Fourth Quarter 2023 Q4 Platform Release30.11.2023 18:00:00 CET | Press release
Q4 Inc. (TSX: QFOR) (“Q4” or “the Company”), the leading capital markets access platform, announced today its fourth quarter 2023 release of innovative enhancements to the Q4 Platform that will continue to deliver value to their clients through seamless workflows, insights, and analytics. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231130813795/en/ Q4 Issuer Dashboard Q4 Platform Release: Fourth Quarter 2023 Issuer Dashboard: Improved Web Management App Issuers can now use the Web Management app to make accelerated website updates and have greater visibility into the status of their web requests. The homepage also gives them direct access to highlighted critical alerts, including activist engagements, and real time updates on events. Engagement Analytics App: Smarter Insights Through the Engagement Analytics app, Investor Relations Officers (“IROs”) will now have access to historical data on investor engagement to more ea
ISFC to Focus on Central Role of Forestry Sector at COP2830.11.2023 17:56:00 CET | Press release
The International Sustainable Forestry Coalition (ISFC) will be representing some of the world’s largest companies engaged in sustainable forestry at COP28, and will be promoting the role of forestry and land-use in the global climate transition. Nations must find a way to reduce emissions by 43% by 2030 if we are to avoid the worst effects of climate change. With greater investment, forestry and land management could contribute up to 25% of the emissions reductions needed to reach net zero. It is widely expected at COP that there will be more focus on the role that sustainably produced timber can play in the built environment, and ISFC will be taking a leading role in these discussions and promoting the expanded contribution of the forestry sector to the decarbonization of the global economy. Dr. David Brand, Convening Chair of ISFC and Executive Chair of New Forest, commented, “The global climate effort requires expanded investment in sustainable land-use and sustainable materials in
Aviz Networks Expands Funding to $10M With New Investments From Accton, Cisco Investments and Wistron30.11.2023 16:32:00 CET | Press release
Aviz Networks, a leader in open networking software for cloud-scale infrastructures serving telecom and enterprises, today announced it has added Cisco Investments to its latest funding expansion, joining existing investors, Moment Ventures, Accton and Wistron. This funding round, now reaching $10M, will accelerate customer momentum for Aviz’s multi-vendor, GenAI-based networking stack along with adoption of SONiC based open networking. Aviz helps organizations achieve the performance and cost benefits of hyperscale networks by removing complexity and supplying AI-driven management features as part of a breakthrough Networking 3.0 software stack. Aviz’s stack supports the fast-growing SONiC open-source network OS (NOS) as well as multi-NOS environments and leverages the power of large-language-models (LLMs) to deliver unparalleled choice and capabilities. The company has seen rapid growth over the past 12 months, scaling its number of customers, revenue, and operational headcount to me
MSCI Appoints Jana Haines as Head of Index30.11.2023 15:14:00 CET | Press release
MSCI Inc. (NYSE: MSCI), a leading provider of mission-critical decision support tools and services for the global investment community, today announced that Jana Haines has joined the firm as Head of Index and as a member of MSCI’s Executive Committee. Based in New York, Ms. Haines will be responsible for the strategic development and execution of MSCI’s global Index product line. She will partner with senior leaders across the firm to manage the Index product development process. Ms. Haines will aim to drive innovation across index categories, including market cap, sustainability, climate, factors, thematics and asset classes, such as fixed income and private assets. "As a longtime business leader, Jana has a proven track record of strategic thinking and a unique understanding of the value of MSCI’s indexes to investors,” said Baer Pettit, President and Chief Operating Officer of MSCI. “Jana’s extensive expertise in the global financial industry will be critical to MSCI building an ev